Our Healthcare System Can’t Afford Diet Drugs

<a href="https://www.nytimes.com/2024/03/04/opinion/ozempic-wegovy-medicare-federal-budget.html" rel="noopener ugc nofollow" target="_blank">The NY Times</a> has estimated the cost and savings to state public insurance programs, health insurance exchange subsidies, and U.S. taxpayers from making the new weight loss class of drugs more broadly available. Under reasonable assumptions and at current prices, making this class of medications available to all obese Americans could eventually cost over $1 trillion per year. That exceeds the savings to the government from reduced diabetes incidence and other health care costs from excess weight by $800 billion annually. In the ongoing battle against obesity, the quest for a miracle solution often leads to the emergence of new diet drugs promising rapid weight loss with minimal effort. However, while these medications may offer short-term results, they are far from being the panacea for the complex issue of obesity. In this article, we’ll explore why relying solely on new diet drugs is not the answer to the obesity epidemic and why a multifaceted approach is necessary for long-term success. <a href="https://richardameyer.medium.com/our-healthcare-system-cant-afford-diet-drugs-0cbdaf95676a">Visit Now</a>